About Bio-Me
Bio-Me is a company based in Oslo (Norway) founded in 2016. Bio-Me has raised $1.32 million across 3 funding rounds from investors including European Union and Katapult. Bio-Me offers products and services including PMP™ Technology, Microbiome Analysis Services, and Diagnostics and Drug Development. Bio-Me operates in a competitive market with competitors including Manus Bio, Kallyope, OxThera, BioCorteX and Chain Biotech, among others.
- Headquarter Oslo, Norway
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website bio-me.com
- Social LinkedIn
- Legal Name Bio-Me As
- Annual Revenue$362.06 K (USD)-20as on Dec 31, 2021
- Net Profit-$798.27 K (USD)-46as on Dec 31, 2021
- EBITDA-$798.27 K (USD)-46as on Dec 31, 2021
- Total Equity Funding$1.32M (USD)
in 3 rounds
- Latest Funding Round$413.1K (USD), Grant
Dec 2022
- InvestorsEuropean Union
& 1 more
Products & Services of Bio-Me
Bio-Me offers a comprehensive portfolio of products and services, including PMP™ Technology, Microbiome Analysis Services, and Diagnostics and Drug Development.
Enables high-volume precision analysis of microbiome samples.
Supports rapid microbiome studies for academia and pharma.
Facilitates clinical tests and drug analysis using microbiome data.
Funding Insights of Bio-Me
Bio-Me has successfully raised a total of $1.32M across 3 strategic funding rounds. The most recent funding activity was a Grant round of $413.1 thousand completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.32M
- Total Rounds 3
- Last Round Grant — $413,097
- First Round $150,000
(Jun 2018)
- Investors Count 2
All 3 funding rounds of Bio-Me with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $413,097 | Grant | – | – | |
| Jul 2021 | $1.17M | Seed | – | – | – |
| Jun 2018 | $150,000 | Seed | – | – |
2 investors in total: 2 institutional.
Investors in Bio-Me
Bio-Me has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include European Union and Katapult.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investment consulting services are provided to guide client portfolios. | 2016 | katapult.vc | Oslo, Norway | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for Bio-Me
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bio-Me
1 people are tracked at Bio-Me (1 in leadership).
| Name | Role | Group |
|---|---|---|
Morten Isaksen | CEO | Leadership |
Complete people profiles for Bio-Me
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Bio-Me
3 dated milestones of Bio-Me across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Bio-Me is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Grant, of $413K.
Competitors of Bio-Me
Bio-Me operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Manus Bio, Kallyope, OxThera, BioCorteX and Chain Biotech, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| manusbio.com | 2011 | Cambridge, United States | $115.93M | – | Phytochemicals are developed using microbial fermentation processes. | |
| kallyope.com | 2014 | New York, United States | $479M | 84 | The gut-brain axis is explored for therapeutic and nutritional innovations. | |
| oxthera.com | 2005 | Stockholm, Sweden | $93.1M | – | Microbial-based drug products for hyperoxaluria treatment are developed. | |
| biocortex.com | 2021 | London, United Kingdom | $5M | – | Human-microbiome platform is developed for drug discovery applications. | |
| chainbiotech.com | 2014 | Nottingham, United Kingdom | $5.88M | 12 | Microbiome-based oral immunotherapies are developed via CADD platform. | |
| mbiomics.com | 2020 | Munich, Germany | $14.04M | – | Genomic platforms for microbiome therapeutics development are provided. | |
| adapsyn.com | 2016 | Hamilton, United States | – | – | Provider of computational tools for bacterial metabolomic and genomic data analysis | |
| microbyre.com | 2017 | San Francisco, United States | $7.67M | – | Genetically engineered microorganisms are developed for biomanufacturing and dairy applications. | |
| moonbio.com | 2015 | Beijing, China | $50.6M | – | Microbial separation and cultivation technologies are developed for various applications. |
Detailed competitors of Bio-Me
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bio-Me
The website of Bio-Me (bio-me.com) receives about 3.6K visits a month.
- Monthly visits3.6K
▼ 3.4% vs previous month
Latest news on Bio-Me
Complete news archive for Bio-Me
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to Bio-Me
10 companies that operate in the same segment as Bio-Me (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Bio-Me
Bio-Me was founded in 2016 and raised its 1st funding round 2 years after it was founded.
Bio-Me is headquartered in Oslo, Norway. It is registered at Oslo, Oslo, Norway.
Morten Isaksen is the current CEO of Bio-Me.
Bio-Me is a funded company, having raised a total of $1.32M across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Jun 2018.
Annual revenue of Bio-Me is $362.06K as on Dec 31, 2021.
Founded in 2016 in Oslo, Norway, Bio-Me operates in the biotechnology sector, focusing on microbiome research. A precision profiling platform is utilized for species, sub-species, and strain-level analysis via targeted quantitative PCR. Samples from biobanks are combined to build a database that supports predictions for disease treatment and prevention options. Leadership is provided by CEO Morten Isaksen.
Bio-Me offers PMP™ Technology, Microbiome Analysis Services, and Diagnostics and Drug Development.
Bio-Me has 2 investors. Key investors include European Union, and Katapult.
Bio-Me operates through Bio-Me As.